Viking Therapeutics (VKTX) Projected to Release Earnings on Wednesday

Viking Therapeutics (NASDAQ:VKTX) is expected to be posting its Q2 2026 results after the market closes on Wednesday, July 29th. Analysts expect the company to announce earnings of ($1.21) per share for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 4:30 PM ET.

Viking Therapeutics (NASDAQ:VKTX) last posted its earnings results on Thursday, April 30th. The biotechnology company reported ($1.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.36). During the same period in the previous year, the company posted ($0.41) EPS. On average, analysts expect Viking Therapeutics to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Viking Therapeutics Trading Up 4.3%

Shares of NASDAQ VKTX opened at $37.95 on Wednesday. Viking Therapeutics has a 12-month low of $22.96 and a 12-month high of $43.15. The firm’s 50-day moving average price is $33.51 and its 200-day moving average price is $32.89. The stock has a market capitalization of $4.41 billion, a price-to-earnings ratio of -9.17 and a beta of 0.66.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Royal Bank of Canada increased its stake in Viking Therapeutics by 13.0% in the 1st quarter. Royal Bank of Canada now owns 347,716 shares of the biotechnology company’s stock worth $8,396,000 after buying an additional 39,886 shares during the period. Integrated Wealth Concepts LLC purchased a new stake in Viking Therapeutics in the 1st quarter valued at about $230,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Viking Therapeutics by 1.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 470,028 shares of the biotechnology company’s stock worth $11,351,000 after acquiring an additional 6,696 shares in the last quarter. Prudential Financial Inc. bought a new position in Viking Therapeutics in the 2nd quarter worth about $196,000. Finally, Northwestern Mutual Wealth Management Co. increased its position in shares of Viking Therapeutics by 29.5% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 2,109 shares of the biotechnology company’s stock worth $56,000 after acquiring an additional 481 shares during the period. 76.03% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on VKTX. Lake Street Capital started coverage on Viking Therapeutics in a research report on Thursday, May 28th. They set a “buy” rating and a $89.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Viking Therapeutics in a report on Friday. BTIG Research reissued a “buy” rating and set a $125.00 target price on shares of Viking Therapeutics in a research report on Friday, May 1st. Morgan Stanley set a $95.00 price target on Viking Therapeutics in a report on Thursday, April 30th. Finally, Cantor Fitzgerald decreased their price target on Viking Therapeutics from $105.00 to $100.00 and set an “overweight” rating on the stock in a report on Thursday, April 30th. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Viking Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $93.60.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Headquartered in San Diego, California, the company’s pipeline leverages small-molecule approaches to target hormone signaling pathways implicated in conditions such as non‐alcoholic steatohepatitis (NASH), dyslipidemia, type 2 diabetes and muscle wasting disorders.

The company’s lead programs include VK2809, a thyroid hormone receptor‐beta agonist designed to reduce liver fat and improve lipid profiles in patients with NASH and dyslipidemia, and VK5211, a selective androgen receptor modulator (SARM) aimed at enhancing muscle mass and function in individuals with muscle wasting conditions.